Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Cancers of unknown primary diagnosed during hospitalization: a population-based study

Authors: William Jones, Gwen Allardice, Iona Scott, Karin Oien, David Brewster, David S. Morrison

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Cancers of Unknown Primary (CUP) are the 3-4th most common causes of cancer death and recent clinical guidelines recommend that patients should be directed to a team dedicated to their care. Our aim was to inform the care of patients diagnosed with CUP during hospital admission.

Methods

Descriptive study using hospital admissions (Scottish Morbidity Record 01) linked to cancer registrations (ICD-10 C77-80) and death records from 1998 to 2011 in West of Scotland, UK (population 2.4 m). Cox proportional hazards models were used to assess effects of baseline variables on survival.

Results

Seven thousand five hundred ninety nine patients were diagnosed with CUP over the study period, 54.4% female, 67.4% aged ≥ 70 years, 36.7% from the most deprived socio-economic quintile. 71% of all diagnoses were made during a hospital admission, among which 88.6% were emergency presentations and the majority (56.3%) were admitted to general medicine. Median length of stay was 15 days and median survival after admission 33 days. Non-specific morphology, emergency admission, age over 60 years, male sex and admission to geriatric medicine were all associated with poorer survival in adjusted analysis.

Conclusions

Patients with a diagnosis of CUP are usually diagnosed during unplanned hospital admissions and have very poor survival. To ensure that patients with CUP are quickly identified and directed to optimal care, increased surveillance and rapid referral pathways will be required.
Literature
1.
go back to reference National Institute for Health and Clinical Excellence: Metastic malignant disease of unknown primary origin: Diagnosis and management of metastatic malignant disease of unknown primary origin. London: NICE; 2010. National Institute for Health and Clinical Excellence: Metastic malignant disease of unknown primary origin: Diagnosis and management of metastatic malignant disease of unknown primary origin. London: NICE; 2010.
2.
go back to reference Shu X, Sundquist K, Sundquist J, Hemminki K. Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev. 2012;21(3):281–8.CrossRefPubMed Shu X, Sundquist K, Sundquist J, Hemminki K. Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur J Cancer Prev. 2012;21(3):281–8.CrossRefPubMed
3.
go back to reference Luke C, Koczwara B, Karapetis C, Pittman K, Price T, Kotasek D, Beckmann K, Brown MP, Roder D. Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health. 2008;32(4):383–9.CrossRefPubMed Luke C, Koczwara B, Karapetis C, Pittman K, Price T, Kotasek D, Beckmann K, Brown MP, Roder D. Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust N Z J Public Health. 2008;32(4):383–9.CrossRefPubMed
4.
go back to reference Urban D, Rao A, Bressel M, Lawrence YR, Mileshkin L. Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer. 2013;109(5):1318–24.CrossRefPubMedPubMedCentral Urban D, Rao A, Bressel M, Lawrence YR, Mileshkin L. Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer. 2013;109(5):1318–24.CrossRefPubMedPubMedCentral
5.
go back to reference Randen M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960–2007. Acta Oncol. 2009;48(6):915–20.CrossRefPubMed Randen M, Rutqvist LE, Johansson H. Cancer patients without a known primary: incidence and survival trends in Sweden 1960–2007. Acta Oncol. 2009;48(6):915–20.CrossRefPubMed
6.
7.
go back to reference Brewster DH, Lang J, Bhatti LA, Thomson CS, Oien KA. Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010. Cancer Epidemiol. 2014;38(3):227–34.CrossRefPubMed Brewster DH, Lang J, Bhatti LA, Thomson CS, Oien KA. Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010. Cancer Epidemiol. 2014;38(3):227–34.CrossRefPubMed
8.
go back to reference Cancer Research UK and National Cancer Intelligence Network. Cancer of unknown primary NCIN and CR-UK data briefing. 2013. Cancer Research UK and National Cancer Intelligence Network. Cancer of unknown primary NCIN and CR-UK data briefing. 2013.
9.
go back to reference Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G, Group EGW. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi64–8.PubMed Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G, Group EGW. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi64–8.PubMed
10.
go back to reference National Cancer Intelligence Network. Routes to diagnosis: cancer of unknown primary – NCIN data briefing. 2014. National Cancer Intelligence Network. Routes to diagnosis: cancer of unknown primary – NCIN data briefing. 2014.
11.
go back to reference Fritz A, Percy C, Jack A. International Classification of Diseases for Oncology. 3rd edn. Geneva: World Health Organisation; 2000. Fritz A, Percy C, Jack A. International Classification of Diseases for Oncology. 3rd edn. Geneva: World Health Organisation; 2000.
13.
go back to reference Greco FA. Cancer of unknown primary site: evolving understanding and management of patients. Clin Adv Hematol Oncol. 2012;10(8):518–24.PubMed Greco FA. Cancer of unknown primary site: evolving understanding and management of patients. Clin Adv Hematol Oncol. 2012;10(8):518–24.PubMed
14.
go back to reference Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: 20 questions to be answered. Ann Oncol. 2010;21:303–7.CrossRef Pavlidis N, Pentheroudakis G. Cancer of unknown primary site: 20 questions to be answered. Ann Oncol. 2010;21:303–7.CrossRef
15.
go back to reference Hemminki K, Ji J, Sundquist J, Shu X. Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol. 2011;29(4):435–40.CrossRefPubMed Hemminki K, Ji J, Sundquist J, Shu X. Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol. 2011;29(4):435–40.CrossRefPubMed
Metadata
Title
Cancers of unknown primary diagnosed during hospitalization: a population-based study
Authors
William Jones
Gwen Allardice
Iona Scott
Karin Oien
David Brewster
David S. Morrison
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3083-1

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine